Kathleen L. Poston

This study identifies sex-specific changes in bone and senescence-related proteins in neurodegenerative diseases using plasma proteomics.

The paper identifies a plasma proteomic signature linked to blood-brain barrier dysfunction, which predicts cognitive decline after ischemic stroke.

The paper develops scalable targeted proteomics assays using the Stellar mass spectrometer for analyzing biofluids, demonstrating high sensitivity and multiplexing capabilities.

The paper uses long-read genome sequencing and multi-omics data to identify structural variants associated with aging and neurodegenerative diseases, finding that SVs are more likely to be causal than SNVs.

The paper demonstrates using data-independent acquisition (DIA) to select peptides for targeted proteomics assays, achieving comparable quantitative precision to existing methods.

CSF YWHAG:NPTX2 synapse protein ratio, from proteomics of 3,416 individuals across six cohorts, explains cognitive impairment beyond amyloid and tau and predicts decline (hazard ratio 15.4).

This study uses single-cell immunoprofiling to identify distinct immune signatures in Lewy body disease compared to other neurodegenerative and immune conditions.

The paper analyzes single exosomes in CSF from Alzheimer's and Parkinson's patients and controls, finding reduced ApoE+ exosomes in Alzheimer's patients.

The paper analyzes synaptic molecular changes in Alzheimer's disease and related conditions using mass cytometry and imaging, identifying disease-specific molecular differences.

The paper analyzes sncRNA-seq data from the PPMI cohort to identify miRNAs associated with Parkinson's disease progression and systemic inflammation.

The paper examines the correlation between CSF sTREM2 and CSF tau levels in Parkinson’s disease and finds that sTREM2 is elevated in PD subgroups with abnormal tau but not Aβ.